PL3060582T3 - Testy do oznaczania biomarkerów układu kalikreiny osoczowej - Google Patents

Testy do oznaczania biomarkerów układu kalikreiny osoczowej

Info

Publication number
PL3060582T3
PL3060582T3 PL14856778T PL14856778T PL3060582T3 PL 3060582 T3 PL3060582 T3 PL 3060582T3 PL 14856778 T PL14856778 T PL 14856778T PL 14856778 T PL14856778 T PL 14856778T PL 3060582 T3 PL3060582 T3 PL 3060582T3
Authority
PL
Poland
Prior art keywords
biomarkers
tests
determination
plasma kallikrein
kallikrein system
Prior art date
Application number
PL14856778T
Other languages
English (en)
Inventor
Daniel J. Sexton
Ryan Faucette
Jon A. Kenniston
Gregory P. Conley
Andrew Nixon
Christopher Tenhoor
Burt Adelman
Original Assignee
Dyax Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52993413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3060582(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dyax Corp. filed Critical Dyax Corp.
Publication of PL3060582T3 publication Critical patent/PL3060582T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21034—Plasma kallikrein (3.4.21.34)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21038—Coagulation factor XIIa (3.4.21.38)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4713—Plasma globulins, lactoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96458—Factor XII (3.4.21.38)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
PL14856778T 2013-10-21 2014-10-17 Testy do oznaczania biomarkerów układu kalikreiny osoczowej PL3060582T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361893505P 2013-10-21 2013-10-21
US201461939837P 2014-02-14 2014-02-14
PCT/US2014/061247 WO2015061183A1 (en) 2013-10-21 2014-10-17 Assays for determining plasma kallikrein system biomarkers
EP14856778.7A EP3060582B1 (en) 2013-10-21 2014-10-17 Assays for determining plasma kallikrein system biomarkers

Publications (1)

Publication Number Publication Date
PL3060582T3 true PL3060582T3 (pl) 2021-05-04

Family

ID=52993413

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14856778T PL3060582T3 (pl) 2013-10-21 2014-10-17 Testy do oznaczania biomarkerów układu kalikreiny osoczowej

Country Status (13)

Country Link
US (2) US11372002B2 (pl)
EP (2) EP3060582B1 (pl)
JP (4) JP6757252B2 (pl)
KR (4) KR102432826B1 (pl)
CN (1) CN105873951A (pl)
AU (3) AU2014340450B2 (pl)
BR (1) BR112016008970B1 (pl)
CA (1) CA2927824C (pl)
DK (1) DK3060582T3 (pl)
ES (1) ES2837858T3 (pl)
IL (3) IL289514B2 (pl)
PL (1) PL3060582T3 (pl)
WO (1) WO2015061183A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62853B1 (sr) 2010-01-06 2022-02-28 Takeda Pharmaceuticals Co Proteini koji vezuju kalikrein plazme
AU2012204202A1 (en) * 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
IL273688B2 (en) 2013-01-20 2024-12-01 Dyax Corp Evaluation and treatment of bradykinin-mediated disorders
EP3060582B1 (en) 2013-10-21 2020-09-23 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
WO2015061182A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Diagnosis and treatment of autoimmune diseases
PT3096798T (pt) 2014-01-21 2021-02-25 Dyax Corp Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário
AU2015235967B2 (en) 2014-03-27 2020-10-22 Takeda Pharmaceutical Company Limited Compositions and methods for treatment of diabetic macular edema
IL305207A (en) * 2015-03-30 2023-10-01 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and their uses to prevent the outbreak of hereditary angioedema
IL311909B1 (en) * 2015-08-13 2025-11-01 Takeda Pharmaceuticals Co Method for assesing the level of drug targeting the contact system in a subject
EP3839514B1 (en) 2015-10-19 2023-12-13 Takeda Pharmaceutical Company Limited Immunoassay to detect cleaved high molecular weight kininogen
AU2016372159B2 (en) 2015-12-15 2022-03-24 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK
JP7319916B2 (ja) 2016-09-16 2023-08-02 武田薬品工業株式会社 遺伝性血管性浮腫のｒｎａバイオマーカー
KR20250073510A (ko) * 2016-09-16 2025-05-27 다케다 파머수티컬 컴패니 리미티드 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커
IL314752A (en) * 2016-09-16 2024-10-01 Takeda Pharmaceuticals Co Metabolite biomarkers for diseases associated with the contact activation system
EP3521828A1 (en) * 2018-01-31 2019-08-07 Centogene AG Method for the diagnosis of hereditary angioedema
US20200407771A1 (en) * 2018-02-22 2020-12-31 The Regents Of The University Of California Threshold-stimulated plasma kallikrein activity as a biomarker for diagnosis of bradykinin-mediated angioedema
CN111057745B (zh) * 2019-12-30 2022-08-12 中国科学院生态环境研究中心 一种物质的血液毒性效应的高通量筛选方法
MX2022008649A (es) 2020-01-13 2022-09-23 Takeda Pharmaceuticals Co Inhibidores de calicreina plasmatica y sus usos para tratar episodios de angioedema hereditario pediatrico.
EP4126219A2 (en) * 2020-04-04 2023-02-08 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
CN113777331A (zh) * 2020-06-09 2021-12-10 张曼 尿液激肽原-1及其多肽片段在烧伤中的应用
CN114166924B (zh) * 2021-12-03 2024-11-22 中国医学科学院北京协和医院 尿液蛋白标志物在诊断遗传性血管水肿中的用途
EP4548103A2 (en) * 2022-06-30 2025-05-07 Takeda Pharmaceutical Company Limited Protein biomarkers for lanadelumab treatment
WO2025153806A1 (en) * 2024-01-15 2025-07-24 Kalvista Pharmaceuticals Limited Methods for determining amidolytic activity

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1312564C (en) 1985-07-12 1993-01-12 Robert W. Colman Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same
US5047323A (en) 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPS63185398A (ja) * 1986-09-10 1988-07-30 Nippon Zoki Pharmaceut Co Ltd 生理活性物質測定法
US4882272A (en) 1986-10-01 1989-11-21 Temple University - Of The Commonwealth System Of Higher Education High molecular weight kininogen assay
US5025796A (en) 1988-12-01 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5472945A (en) 1991-08-13 1995-12-05 Temple University- Of The Commonwealth System Of Higher Education Modulation of blood pressure and inhibition of platelet activation with kininogen fragment
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
PT739355E (pt) 1994-01-11 2005-01-31 Dyax Corp Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos
JPH1084995A (ja) 1996-09-12 1998-04-07 Nippon Zoki Pharmaceut Co Ltd 血液凝固第ｘｉｉ因子活性化法
US5789261A (en) 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
US6242210B1 (en) * 1997-05-20 2001-06-05 Actinova Limited Treatment of bacterial infections
JP4346798B2 (ja) 1999-08-19 2009-10-21 協和メデックス株式会社 Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。
US6994852B1 (en) 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US7678541B2 (en) * 2000-11-21 2010-03-16 Hologic, Inc. Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction
JP2002221519A (ja) 2001-01-29 2002-08-09 Sysmex Corp 抗凝固剤およびそれを用いた抗凝固剤処理方法
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
CA2488558C (en) 2002-06-07 2013-08-20 Dyax Corp. Prevention and reduction of blood loss
AU2003281287A1 (en) 2002-07-04 2004-01-23 Oxford Glycosciences (Uk) Ltd Toxicity markers
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1598428A1 (en) * 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
AU2005271523B2 (en) 2004-08-03 2011-09-15 Dyax Corp. hk1-binding proteins
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
PT1981519T (pt) 2005-12-29 2018-02-23 Dyax Corp Inibição de protéases
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
AU2007281220B2 (en) 2006-07-31 2013-08-15 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
WO2008064336A2 (en) 2006-11-22 2008-05-29 Inivitrogen Corporation Autoimmune disease biomarkers
EP2195010A4 (en) 2007-08-21 2012-03-14 Genzyme Corp TREATMENT WITH INHIBITORS OF KALLIKREINE
JP5424331B2 (ja) 2007-10-18 2014-02-26 国立大学法人 鹿児島大学 肝疾患診断用バイオマーカー
CA2703264A1 (en) 2007-10-22 2009-04-30 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
AU2009269257A1 (en) 2008-07-07 2010-01-14 Nippon Zoki Pharmaceutical Co., Ltd. Method for detection of fibromyalgia
JP2012507723A (ja) 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
EP2369930A4 (en) * 2008-12-02 2012-10-03 Joslin Diabetes Ct METHOD OF REDUCING BLOOD PRESSURE USING PLASMATIC KALLICREIN INHIBITORS
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
FR2942233B1 (fr) 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
KR101077275B1 (ko) 2009-05-07 2011-10-27 한국기초과학지원연구원 당단백질의 당쇄화를 이용한 암 진단 방법
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
JP2013515000A (ja) 2009-12-18 2013-05-02 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬のプロドラッグ
US9206123B2 (en) 2009-12-18 2015-12-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
RS62853B1 (sr) 2010-01-06 2022-02-28 Takeda Pharmaceuticals Co Proteini koji vezuju kalikrein plazme
WO2012009447A2 (en) 2010-07-13 2012-01-19 University Of Rochester THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
US10299714B2 (en) 2010-12-02 2019-05-28 Becton, Dickinson And Company Blood collection devices containing blood stabilization agent including variegin or analog thereof and/or a polysulfated disaccharide
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
CA2838984A1 (en) * 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
US9187749B2 (en) 2011-06-10 2015-11-17 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
FR2983215B1 (fr) * 2011-11-28 2013-12-20 Univ Grenoble 1 Dosage de la capacite de controle de c1inh
IL273688B2 (en) 2013-01-20 2024-12-01 Dyax Corp Evaluation and treatment of bradykinin-mediated disorders
EP2950718A4 (en) 2013-02-01 2016-09-21 Becton Dickinson Co BLUTSAMMELVORRICHTUNGEN WITH CONTACT PATH -HEMMENDEN ADDITIVES
WO2015061182A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Diagnosis and treatment of autoimmune diseases
EP3060582B1 (en) 2013-10-21 2020-09-23 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
PT3096798T (pt) 2014-01-21 2021-02-25 Dyax Corp Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário
EP3839514B1 (en) 2015-10-19 2023-12-13 Takeda Pharmaceutical Company Limited Immunoassay to detect cleaved high molecular weight kininogen
AU2016372159B2 (en) 2015-12-15 2022-03-24 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK
US20230072523A1 (en) 2020-01-28 2023-03-09 Orgenesis Inc. Process and system for acellular therapy

Also Published As

Publication number Publication date
IL245205B (en) 2020-05-31
AU2024203355A1 (en) 2024-06-06
IL245205A0 (en) 2016-06-30
US12442824B2 (en) 2025-10-14
US20160252527A1 (en) 2016-09-01
BR112016008970A2 (pt) 2017-09-19
JP2016536012A (ja) 2016-11-24
JP2021003114A (ja) 2021-01-14
KR20250066486A (ko) 2025-05-13
IL274055A (en) 2020-06-30
IL289514B1 (en) 2023-09-01
EP3808857B1 (en) 2025-12-10
US20220291232A1 (en) 2022-09-15
JP7668772B2 (ja) 2025-04-25
KR20160093604A (ko) 2016-08-08
EP3808857C0 (en) 2025-12-10
EP3060582A1 (en) 2016-08-31
JP2022188017A (ja) 2022-12-20
CN105873951A (zh) 2016-08-17
BR112016008970B1 (pt) 2023-12-26
EP3060582A4 (en) 2017-07-19
AU2014340450A1 (en) 2016-06-02
ES2837858T3 (es) 2021-07-01
AU2020217316A1 (en) 2020-08-27
CA2927824A1 (en) 2015-04-30
IL289514A (en) 2022-03-01
DK3060582T3 (da) 2020-12-21
EP3808857A1 (en) 2021-04-21
IL289514B2 (en) 2024-01-01
EP3060582B1 (en) 2020-09-23
JP7135039B2 (ja) 2022-09-12
KR20230054745A (ko) 2023-04-25
AU2014340450B2 (en) 2020-05-21
KR102432826B1 (ko) 2022-08-16
CA2927824C (en) 2025-06-17
KR20220119171A (ko) 2022-08-26
US11372002B2 (en) 2022-06-28
JP6757252B2 (ja) 2020-09-16
AU2020217316B2 (en) 2024-02-22
IL274055B (en) 2022-02-01
WO2015061183A1 (en) 2015-04-30
KR102521947B1 (ko) 2023-04-14
JP2024150637A (ja) 2024-10-23

Similar Documents

Publication Publication Date Title
IL289514B1 (en) Assays for determining plasma kallikrein system biomarkers
IL253756A0 (en) Biomarker panel for the detection of cancer
DK3527563T3 (da) Dna-pk-inhibitorer
EP2964234A4 (en) Heterologous untranslated regions for mrna
DK3011059T3 (da) Biomarkør-identifikation
EP2972393A4 (en) BIOMARKERS AND METHOD FOR PREDICTING PREECLAMPSIA
DK3010503T3 (da) Hidtil ukendte bicykliske bromodomæne-inhibitorer
HUE046398T2 (hu) Génszerkesztésre szolgáló CAS-variánsok
DK2879615T3 (da) Fremgangsmåde til at bestemme sandsynlighed for brunst
DK3182092T3 (da) Fremgangsmåde til måling af borefluidegenskaber
DE112014001845T8 (de) Authentifizierung für Erkennungssysteme
EP3488225A4 (en) GAS MEASUREMENT SYSTEM
EP3304093A4 (en) VALIDATION OF BIOMARK MEASUREMENT
EP2965077A4 (en) METHOD OF CANCER DETECTION
EP3338088A4 (en) BIOMARKER FOR CORONARY DISEASE
DK3004875T3 (da) Prædiktiv biomarkør til cancerterapi
HUE064630T2 (hu) Prognosztikai biomarkerek TTK-inhibitoros kemoterápiához
DK3058344T3 (da) Fremgangsmåder til måling af carbonhydridfluiders tilsmudsningstendens
HUE043373T2 (hu) Szívelégtelenség utáni rehospitalizáció biomarkere
EP2979072A4 (en) LEAK DETECTOR
TH1401007440B (th) ระบบไดนาโมมิเตอร์
EP2972362A4 (en) MULTIBIOMARKER-BIOSENSOR
TH1401004965B (th) ระบบไดนาโมมิเตอร์
TH155965B (th) กระบวนการสำหรับการแยกของผสมก๊าซ
TH1501002496A (th) ลิ้นสำหรับการวัดคุมของไหล